INVITRO ACTIVITY OF TOSUFLOXACIN (A-61827-T-3262) AGAINST SELECTED GENITAL PATHOGENS

The in vitro activity of tosufloxacin (A-61827; T-3262) against 15 clinical isolates of Chlamydia trachomatis and 31 recent clinical isolates of Nesseria gonorrhoeae, including 15 spectinomycin-resistant N. gonorrhoeae and 16 penicillinase-producing N. gonorrhoeae, was determined. Tosufloxacin was compared with doxycycline, ciprofloxacin, and temafloxacin against C. trachomatis. Susceptibility testing was performed by using McCoy cell monolayers. The in vitro of tosufloxacin against N. gonorrhoeae was compared with that of ciprofloxacin, temafloxacin, doxycycline, ceftriaxone, and spectinomycin by using an agar dilution method. Tosufloxacin was as active as temafloxacin against C. trachomatis (MIC for 90% of strains tested [MBC90], 0.25 μg/ml) and was almost as active as doxycycline (MIC90, 0.06 μg/ml; MBC90, 0.125 μg/ml). Ciprofloxacin, temafloxacin, and tosufloxcin were extremely active against N. gonorrhoeae, including spectinomycin-resistant N. gonorrhoeae and penicillinase-producing N. gonorrhoeae, with MIC90s of 0.004, 0.015, and 0.008 μg/ml, respectively. Ceftriaxone was slightly less active (MIC90, 0.03 μg/ml), and doxycycline was the least active drug tested (MIC90, 4.0 μg/ml). Tosufloxacin and temafloxacin had excellent activity against the C. trachomatis and N. gonorrhoeae strains tested.